Aldactone in cardiorenal AKI
Reading File
Reading File
Finding Sources
Finding Sources
Searching PubMed
spironolactone AND acute kidney injury
Searching the Web
2022 AHA ACC HFSA heart failure guideline mineralocorticoid receptor antagonist eGFR 30 potassium 5.0
Usually hold Aldactone (spironolactone) during active cardiorenal AKI if there is hyperkalemia, oliguria, hypotension, or a significant/ongoing rise in creatinine. Its immediate role is not acute decongestion, and it can worsen or precipitate dangerous hyperkalemia when GFR falls.
For HFrEF, spironolactone is a mortality-reducing chronic therapy, but generally use or resume it only when:
- eGFR >30 mL/min/1.73 m²
- K <5.0 mEq/L to initiate or restart
- Renal function and perfusion are stabilizing
- Close potassium/creatinine surveillance is feasible, especially with ACEi/ARB/ARNI, trimethoprim, NSAIDs, potassium supplements, or advanced CKD. The ACC heart-failure guideline summary lists MRAs as foundational HFrEF therapy, but renal function and potassium determine safety.
Practical inpatient approach
- K ≥5.5 mEq/L, rapidly rising K, eGFR <30, severe AKI/oliguria, or shock: hold spironolactone.
- Congested but perfusing, mild creatinine increase, K clearly normal: do not automatically stop all HF therapy solely for creatinine. Prioritize adequate IV loop-diuretic decongestion, assess urine output, BP, volume status, and serial labs. Whether to continue spironolactone is individualized, but many clinicians pause it temporarily until AKI is stable because the near-term benefit is modest compared with its potassium risk.
- Restart: once improving/stable, at low dose, with repeat K/creatinine within about 3 days and again at 1 week, then frequently during titration.
Do not use Aldactone as the main acute diuretic in cardiorenal AKI. It is mainly an adjunct for chronic HFrEF and can be useful later when renal function and potassium allow.
This is a shared conversation. Sign in to Orris to start your own chat.